Muscle mass and prevalence of sarcopenia in rheumatoid arthritis patients.

BRANCE ML; PONS-ESTEL BA; QUAGLIATO NJ; JORFEN M; BERBOTTO G; CORTESE N; RAGGIO JC; SOLDANO J; PALATNIK M; CHAVERO I; SÁNCHEZ A; DEL RIO L; DI GREGORIO S; BRUN LR

Barcelona

Congreso; World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2020); 2020

International Osteoporosis Foundation

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by symmetric polyarthritis that can lead to joint deformity and disability. In addition, bone and muscle are also affected. Aim: to evaluate the muscle mass and the prevalence of sarcopenia in patients with RA. Patients y methods: Adults RA patients (n=105) of both sexes and 100 subjects as control group (CG) matched by age, sex and body mass index (BMI) were included. Sarcopenia was defined according to the new consensus of the European Working Group on Sarcopenia in Older People (EWGSOP2) as low muscle strength plus low muscle quantity. If low physical performance was also found, sarcopenia was considered severe. Whole-body composition was measured by dual-energy X-ray absorptiometry (DXA, Hologic Discovery Wi). Muscle strength was evaluated by hand-grip strength (Baseline Hand Dynamometer, USA) in the dominant hand. The physical performance was evaluated by sit to stand, timed up and go and 8-foot walking test. The distribution of the data was evaluated with the Shapiro-Wilk test and parametric or non-parametric tests were used as appropriate. Data were expressed as mean±SD and p